Identifying Which Breast Lesions Will Progress to Cancer Can Help Avoid Overtreatment

Breast cancer remains one of the most commonly diagnosed cancers worldwide, but not all breast abnormalities detected during screening require immediate intervention. A growing body of research focuses on distinguishing between breast lesions that are likely to progress to invasive cancer and those that are indolent or benign. Accurately identifying which lesions warrant treatment versus those that can be safely monitored is critical to reducing overtreatment, minimizing patient anxiety, and avoiding unnecessary side effects from therapies such as surgery, radiation, or chemotherapy.

According to the American Cancer Society, approximately 1 in 8 women in the United States will develop invasive breast cancer during their lifetime. However, advances in imaging and pathology have led to increased detection of early-stage abnormalities, including ductal carcinoma in situ (DCIS) and atypical hyperplasia, some of which may never progress to life-threatening disease.

Understanding Breast Lesions and Cancer Risk

Breast lesions detected through mammography, ultrasound, or MRI vary widely in their biological behavior. Pathologists classify these abnormalities based on cellular atypia, architectural distortion, and molecular markers. Key categories include:

• Benign lesions: Such as fibroadenomas or simple cysts, which carry no significant cancer risk.
• High-risk lesions: Including atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS), which indicate increased future risk but are not cancer themselves.
• Ductal carcinoma in situ (DCIS): A non-invasive condition where abnormal cells are confined to the milk ducts. Whereas considered Stage 0 cancer, not all DCIS progresses to invasive disease.

The challenge lies in predicting which of these lesions will evolve into invasive breast cancer and which can be managed with active surveillance.

Advances in Risk Stratification and Biomarkers

Recent research has focused on identifying molecular and histological features that help stratify risk more precisely. For example, the Oncotype DX DCIS Score test analyzes gene expression in DCIS tissue to predict the likelihood of recurrence or progression to invasive cancer. Studies show that women with a low DCIS Score may safely avoid radiation therapy after lumpectomy without significantly increasing their risk of recurrence.

Similarly, studies published in JAMA Oncology have demonstrated that incorporating biomarkers such as estrogen receptor (ER), progesterone receptor (PR), HER2 status, and Ki-67 proliferation index improves prediction of which DCIS cases are likely to progress.

Emerging technologies like radiomics — which extract quantitative features from medical images — and artificial intelligence (AI) models trained on large datasets of mammograms and pathology slides are also showing promise in distinguishing low-risk from high-risk lesions before biopsy.

Clinical Implications: Toward Personalized Management

Overtreatment in breast cancer screening remains a significant concern. A 2018 study in JAMA Internal Medicine estimated that up to 20% of screen-detected breast cancers may represent overdiagnosis — meaning they would not have caused symptoms or death if left untreated.

By improving risk prediction, clinicians can tailor management strategies:

• Low-risk DCIS or atypical hyperplasia may be managed with hormonal therapy (e.g., tamoxifen) and close imaging follow-up instead of immediate surgery.
• Intermediate-risk lesions might benefit from clinical trial participation or enhanced surveillance.
• High-risk lesions with aggressive molecular profiles warrant timely intervention.

This shift toward personalized, risk-adapted care aligns with broader efforts in oncology to reduce treatment burden while maintaining survival outcomes.

Ongoing Research and Future Directions

Large-scale trials are actively investigating whether active surveillance is safe for select low-risk breast lesions. The COMET (Comparison of Operative to Monitoring and Endocrine Therapy) trial, led by researchers at Duke University, is comparing outcomes in women with low-risk DCIS who undergo either standard surgery or active monitoring with imaging and endocrine therapy. Early results suggest that monitoring may be a viable alternative for a carefully selected subgroup.

the COMPASS-DCIS registry is collecting real-world data to better understand the natural history of DCIS and refine risk prediction models.

Experts emphasize that while overtreatment must be avoided, any shift toward surveillance requires rigorous patient selection, shared decision-making, and long-term follow-up to ensure safety.

Key Takeaways

• Not all breast lesions detected during screening progress to invasive cancer; some are indolent and may not require immediate treatment.
• Molecular testing (e.g., Oncotype DX DCIS Score), biomarker analysis, and AI-assisted imaging are improving the ability to predict which lesions are likely to progress.
• Avoiding overtreatment reduces physical, emotional, and financial burdens on patients without compromising long-term survival in appropriately selected individuals.
• Active surveillance is being studied as a safe alternative to surgery for low-risk DCIS and high-risk lesions, though it requires careful monitoring and patient consent.
• Shared decision-making between patients and clinicians is essential when weighing the risks and benefits of treatment versus monitoring.

Frequently Asked Questions (FAQ)

What is ductal carcinoma in situ (DCIS)?

DCIS is a non-invasive breast condition where abnormal cells are found in the lining of the milk ducts but have not spread into surrounding breast tissue. It is considered Stage 0 breast cancer, but not all cases progress to invasive disease.

Can some breast lesions be safely monitored instead of treated?

Yes, for certain low-risk lesions — such as low-grade DCIS or atypical hyperplasia — active surveillance with regular imaging and possibly hormonal therapy may be an appropriate alternative to immediate surgery, particularly when guided by risk assessment tools.

What tests help determine if a breast lesion will progress to cancer?

Tests include histopathological analysis, hormone receptor status (ER/PR/HER2), proliferation markers like Ki-67, genomic assays such as the Oncotype DX DCIS Score, and emerging AI-based imaging analytics.

Is active surveillance for DCIS widely accepted?

While still investigational, active surveillance is being evaluated in clinical trials like COMET. It is not yet standard of care but may become an option for select patients in the future.

How can I discuss my options with my doctor?

Ask about your lesion’s specific characteristics, your personal risk factors, and whether genomic or biomarker testing is available. Request a conversation about the risks and benefits of treatment versus monitoring based on your individual situation.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment decisions.